SangStat Thymoglobulin May Need Blinded Study For Induction Therapy sBLA
Executive Summary
SangStat may need to conduct a blinded, placebo-controlled trial for Thymoglobulin as induction therapy for high-risk kidney transplant patients before filing a supplemental BLA, CEO Jean-Jacques Bienaime reports